Key Takeaways Guggenheim upgraded Eli Lilly’s price target to $1,273 from $1,235 while reaffirming its Buy recommendation Shares currently hover near $1,189, reflecting a 51% gain over the tr
Guggenheim’s Seamus Fernandez elevated his price objective for Eli Lilly shares to $1,273 from $1,235 this Monday while maintaining his Buy recommendation. This revised target represents approximately 7% upside from the stock’s current trading level of around $1,189.
Over the past year, LLY shares have surged 51%, propelling the pharmaceutical powerhouse to a market capitalization of approximately $1.06 trillion. The stock is currently trading close to its 52-week peak of $1,249.
Fernandez refreshed his financial model in anticipation of Eli Lilly’s second-quarter financial release, scheduled for August 5, incorporating updated prescription data and currency exchange rate projections. The firm’s Q2 revenue forecast now stands at $20.66 billion, exceeding the consensus analyst estimate of $20.55 billion.
Domestic prescription data for tirzepatide — marketed under the brand names Zepbound and Mounjaro — demonstrates robust expansion, forming the foundation of Guggenheim’s quarterly projections. The company’s revenue has expanded 47% on a year-over-year basis, reaching $72.25 billion across the trailing twelve months.
Eli Lilly’s recently introduced oral obesity medication Foundayo debuted in April, prompting Guggenheim to temper its short-term sales projections due to the launch’s nascent stage. Nevertheless, analysts highlighted that aggressive consumer-facing marketing campaigns only commenced in early June, suggesting the potential for stronger sales momentum ahead.
Guggenheim anticipates the upcoming Q2 conference call will emphasize revised guidance, global market penetration strategies, and Medicare reimbursement coverage for the company’s weight management therapies.
Regarding the development pipeline, Guggenheim enhanced its probability of success assessment for retatrutide — a next-wave obesity treatment — from 70% to 85%. This adjustment follows clinical data unveiled at the American Diabetes Association’s recent conference. Analysts project that retatrutide could generate over $25 billion in annual sales by 2035.
Guggenheim’s bullish stance finds support across the analyst community. Truist Securities elevated its LLY price objective to $1,370, emphasizing robust domestic prescription momentum for Zepbound and Mounjaro. Cantor Fitzgerald established a $1,350 target alongside an Overweight rating.
RBC Capital maintained its Outperform designation with a $1,250 price objective, highlighting favorable long-term growth prospects.
Among 22 Wall Street analysts covering the stock, LLY commands a consensus Strong Buy rating, comprised of 20 Buy ratings and two Hold ratings issued within the past three months.
The mean price target among this analyst cohort stands at $1,294.06, suggesting approximately 17% appreciation potential from present levels.
Eli Lilly will also showcase 16 research abstracts at the 2026 Alzheimer’s Association International Conference in London, featuring data on its Alzheimer’s therapy Kisunla and associated clinical outcomes.
The pharmaceutical giant releases its Q2 financial results on August 5.
The post Guggenheim Ups Eli Lilly (LLY) Price Target to $1,273 on Pipeline Strength appeared first on Blockonomi.
